Current management of hemolytic disease of the newborn infant.
D000649:Amniocentesis; D000906:Antibodies / Q000032:analysis; D001787:Blood Group Incompatibility / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D001805:Blood Transfusion, Intrauterine / Q000009:adverse effects; D036861:Delivery, Obstetric; D004899:Erythroblastosis, Fetal / Q000517:prevention & control / Q000628:therapy*; D005078:Exchange Transfusion, Whole Blood; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007743:Labor, Obstetric; D008722:Methods; D009339:Needles / Q000009:adverse effects; D010298:Parity; D010789:Phototherapy; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000517:prevention & control / Q000628:therapy; D011295:Prenatal Care; D012204:Rh-Hr Blood-Group System; D005719:gamma-Globulins / Q000627:therapeutic use
D000906:Antibodies; D012204:Rh-Hr Blood-Group System; D005719:gamma-Globulins